Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
Subst Abus ; 40(1): 61-65, 2019.
Article in English | MEDLINE | ID: mdl-30475162

ABSTRACT

Background: Overdose education and naloxone distribution (OEND) to people at risk of witnessing or experiencing an opioid overdose has traditionally been provided through harm reduction agencies. Expanding OEND to inpatient general medical settings may reach at-risk individuals who do not access harm reduction services and have not been trained. An OEND program targeting inpatients was developed, piloted, and evaluated on 2 general medicine floors at Montefiore Medical Center, a large urban academic medical center in Bronx, New York. Methods: The planning committee consisted of 10 resident physicians and 2 faculty mentors. A consult service model was piloted, whereby the primary inpatient care team paged the consult team (consisting of rotating members from the planning committee) for any newly admitted patient who had used any opioid in the year prior to admission. Consult team members assessed patients for eligibility and provided OEND to eligible patients through a short video training. Upon completion, patients received a take-home naloxone kit. To evaluate the program, a retrospective chart review over the first year (April 2016 to March 2017) of the pilot was conducted. Results: Overall, consults on 80 patients were received. Of these, 74 were eligible and the consult team successfully trained 50 (68%). Current opioid analgesic use of ≥50 morphine milligram equivalents daily was the most common eligibility criterion met (38%). Twenty-four percent of patients were admitted for an opioid-related adverse event, the most common being opioid overdose (9%), then opioid withdrawal (8%), skin complication related to injecting (5%), and opioid intoxication (2%). Twenty-five percent had experienced an overdose, 35% had witnessed an overdose in their lifetime, and 83% had never received OEND previously. Conclusions: Integrating OEND into general inpatient medical care is possible and can reach high-risk patients who have not received OEND previously. Future research should identify the optimal way of implementing this service.


Subject(s)
Drug Overdose/drug therapy , Inpatients/education , Naloxone/therapeutic use , Patient Education as Topic , Academic Medical Centers , Adult , Aged , Aged, 80 and over , Analgesics, Opioid/adverse effects , Female , Humans , Inpatients/statistics & numerical data , Male , Middle Aged , Narcotic Antagonists/therapeutic use , Patient Education as Topic/methods , Pilot Projects , Program Development , Program Evaluation , Young Adult
3.
Am J Infect Control ; 43(11): 1261-3, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26297524

ABSTRACT

To identify independent predictors for isolation of CTX-M-type extended-spectrum ß-lactamase-producing Escherichia coli (CTX-M E coli) in older adults (>65 years old), 87 cases with CTX-M E coli isolation were compared with matched controls without E coli isolation. Institutionalized residence, multiple comorbidities, and urinary catheter were independent predictors of CTX-M E coli among older adults.


Subject(s)
Escherichia coli Infections/epidemiology , Escherichia coli/enzymology , beta-Lactamases/metabolism , Aged , Aged, 80 and over , Case-Control Studies , Cohort Studies , Escherichia coli/isolation & purification , Escherichia coli Infections/microbiology , Female , Humans , Male , Risk Factors
4.
Am J Infect Control ; 42(5): 565-8, 2014 May.
Article in English | MEDLINE | ID: mdl-24773798

ABSTRACT

Clinical outcomes of older and younger adults with extended-spectrum ß-lactamase-producing Escherichia coli isolation were compared. Two hundred thirty-two older adults (aged ≥65 years), and 145 younger adults with infection were identified between February 2010 and July 2011. After controlling for the propensity score and receipt of effective therapy, older adults were not at increased risk for adverse outcomes.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Escherichia coli Infections/drug therapy , Escherichia coli Infections/microbiology , Escherichia coli/enzymology , Escherichia coli/isolation & purification , beta-Lactamases/metabolism , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Risk Assessment , Treatment Failure , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...